We advised InSilico Medicine on its IPO and HKEX listing

Davis Polk advised InSilico Medicine on its initial public offering and listing on the Hong Kong Stock Exchange in reliance on Rule 144A and Regulation S. The gross proceeds from the offering amounted to approximately HK$2.62 billion, assuming the over-allotment option will be exercised in full.

InSilico Medicine is a global AI-driven drug discovery and development company. Leveraging its proprietary generative AI platform, Pharma.AI, InSilico Medicine has generated more than 20 clinical or IND-enabling-stage assets, three of which are out-licensed to international pharmaceutical and healthcare companies with the maximum total contract value of up to $2.1 billion.

The Davis Polk corporate team included partners James C. Lin, Xuelin (Steve) Wang and Jason Xu, counsel - registered foreign lawyer Jennifer (Yujia) Jiang, registered foreign lawyer Eva Xu and associates Edwin Lee, Andrew Pu and Bobby Yung. Counsel Alon Gurfinkel provided tax advice. Counsel Sarah E. Kim provided advice regarding the Investment Company Act of 1940. Members of the Davis Polk team are based in the Hong Kong, Beijing, New York and London offices.

Copy link to share post